El cumplimiento terapéutico con insulina en el tratamiento de la diabetes mellitus tipo 2: estudio CUMINDIAB

Contreras, E. Márquez; Claros, Nieves Martell; Gil-Guillén, Vicente Francisco; Martínez, J.J. Casado; Pablos, J.L. Martín de; García, J.F. Cepero; González, Rosa Chaves; Ortega, Alfredo Encuentra

doi:10.1016/j.aprim.2010.11.013

Cited by 17 publications

(8 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A recent study by Marquez et al21 found that one quarter of diabetic patients did not comply with their treatment. A review by Cramer et al22 of 39 studies found that the rate of persistence at 12 months was 63% and compliance with oral antidiabetics was 58%, and this was similar for all therapeutic classes analyzed.…”

Section: Discussionmentioning

confidence: 98%

“…Although more studies comparing the use of combination therapy are needed to reinforce the consistency of these results, it seems clear that the role of DPP-4 inhibitors (eg, vildagliptin) in the therapeutic armamentarium for T2DM is evolving rapidly, although long-term data evaluating their effect on metabolic control are lacking 24,25. The available evidence indicates that a direct association between compliance and control is beyond doubt 6,21,23…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Use of metformin and vildagliptin for treatment of type 2 diabetes in the elderly

Sicras‐Mainar

Navarro‐Artieda

2014

DDDT

View full text Add to dashboard Cite

BackgroundThe aim of this study was to describe the clinical (treatment adherence, metabolic control, hypoglycemia, and macrovascular complications) and economic (resource use and costs) consequences of using a combination of metformin + vildagliptin to treat type 2 diabetes in elderly patients seen in daily clinical practice.MethodsWe conducted a multicenter, retrospective, observational study that included patients aged ≥65 years treated with metformin who started a second oral antidiabetic therapy during the years 2008–2009. There were two groups of patients: a study group receiving metformin + vildagliptin and a reference group receiving metformin + other oral antidiabetics (sulfonylureas or glitazones). The main measures were comorbidity, compliance/persistence, metabolic control (glycosylated hemoglobin <7%), complications (hypoglycemic, macrovascular), and total costs. The patients were followed for 2 years.ResultsWe recruited 987 patients (49.1% male) of mean age 74.2 years. There were 270 (27.4%) patients in the metformin + vildagliptin group and 717 (72.6%) in the reference group. Vildagliptin-treated patients had significantly (P<0.05) improved compliance (68.3% versus 62.5%, respectively), persistence (61.5% versus 55.1%), and metabolic control (63.3% versus 57.6%). They also had lower rates of hypoglycemia (17.4% versus 42.8%) and cardiovascular events (4.4% versus 8.6%) and lower total costs (€2,544 versus €2,699, P<0.05).ConclusionPatients treated with metformin and vildagliptin showed better adherence and metabolic control and lower rates of hypoglycemia, resulting in lower health care costs for the national health system.

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

Use of metformin and vildagliptin for treatment of type 2 diabetes in the elderly

Sicras‐Mainar

Navarro‐Artieda

2014

DDDT

View full text Add to dashboard Cite

show abstract

“…En un registro publicado en el año 2012 se puso de manifiesto que solo el 56% de los pacientes con DM2 lograron el control metabólico, a pesar de que aproximadamente el 78% de los pacientes seguía tratamiento con antidiabéticos orales o con insulina 11 . Por otro lado, según otros estudios la tasa de incumplimiento se sitúa entre el 30 y el 51% entre pacientes con DM2 que toman antidiabéticos orales6, 7 y cerca del 25% en pacientes insulinizados8, 9.…”

Section: Discussionunclassified

“…Por un lado, es posible que el paciente ni siquiera comience a tomar la medicación, o puede comenzar a tomarla del modo adecuado pero al cabo de un tiempo abandonarla prematuramente. Además, el cumplimiento puede variar en el tiempo, tal y como se ha descrito en otros estudios, observándose un descenso del porcentaje de pacientes cumplidores, que pasa del 82,5% en los primeros 6 meses de tratamiento al 71,8% en los últimos 6 meses en pacientes con DM2 que usaban insulina 8 .…”

Section: Discussionunclassified

“…La adherencia terapéutica puede definirse como la medida en que el paciente asume las normas o consejos dados por el profesional sanitario, tanto desde el punto de vista de hábitos o estilo de vida recomendados como del propio tratamiento farmacológico prescrito 5 . La falta de adherencia se sitúa entre el 30 y el 51% en los pacientes con DM tipo 2 (DM2) que toman antidiabéticos orales6, 7, y de cerca del 25% en pacientes insulinizados8, 9.…”

Section: Introductionunclassified

See 1 more Smart Citation

Abordaje de la adherencia en diabetes mellitus tipo 2: situación actual y propuesta de posibles soluciones

Orozco‐Beltrán

Mata-Cases²,

Artola³

et al. 2016

Atención Primaria

View full text Add to dashboard Cite

show abstract

Patient Preferences for Pharmacological Diabetes Treatment Among People with Diabetes in Spain: A Discrete Choice Experiment

et al. 2021

View full text Add to dashboard Cite

Introduction The aim of the project was to describe the preferences related to the medication attributes of people with diabetes mellitus (DM) treated in Spain. Methods The project was carried out in four different phases. In phase A, a Steering Committee defined and selected a total of 18 attributes for treating DM and grouped them into four categories: health outcomes, adverse events, treatment characteristics and cost of treatment. In phase B, a questionnaire according to a discrete choice experiment (DCE) methodology was developed. In phase C, the online DCE survey was sent to members of associations of people with DM from the Spanish Diabetes Federation (FEDE). Finally, in phase D, the results were discussed in a deliberative process. Results Of the 238 participants who completed the questionnaire (May–September 2020), 231 were included (mean age, 58 years; males, 62%). The DCE results showed that the best-valued category was health outcomes (39.67%), followed by adverse events (26.85%), treatment characteristics (21.70%) and treatment costs (11.77%). Ten of 18 attributes had a significant effect on participants’ choice ( p < 0.05) and the highest relative importance value: blood pressure reduction (12.82%), hypoglycaemia (12.77%), HbA 1c level reduction (8.54%), cost of the medication (8.13%), needle/tablet size (7.20%), weight change (6.72%), risk of genitourinary infections (6.36%), gastrointestinal problems (5.82%), improved kidney function (5.53%) and administration route (5.41%). Conclusions People with DM prefer a treatment that generates benefits in measurable health effects (reducing blood pressure and HbA 1c level, while not risking hypoglycaemia) and a convenient route of administration. Considering the preferences of people with DM could generate better clinical results and therapeutic adherence, reducing morbidity, mortality and disease burden. Supplementary Information The online version contains supplementary material available at 10.1007/s13300-021-01178-9.

show abstract

El cumplimiento terapéutico con insulina en el tratamiento de la diabetes mellitus tipo 2: estudio CUMINDIAB

Abstract: A quarter of the diabetic patients did not comply with their insulin treatment.

Cited by 17 publications

References 19 publications

Use of metformin and vildagliptin for treatment of type 2 diabetes in the elderly

Use of metformin and vildagliptin for treatment of type 2 diabetes in the elderly

Abordaje de la adherencia en diabetes mellitus tipo 2: situación actual y propuesta de posibles soluciones

Patient Preferences for Pharmacological Diabetes Treatment Among People with Diabetes in Spain: A Discrete Choice Experiment

Contact Info

Product

Resources

About